MA45801A1 - Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptine - Google Patents

Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptine

Info

Publication number
MA45801A1
MA45801A1 MA45801A MA45801A MA45801A1 MA 45801 A1 MA45801 A1 MA 45801A1 MA 45801 A MA45801 A MA 45801A MA 45801 A MA45801 A MA 45801A MA 45801 A1 MA45801 A1 MA 45801A1
Authority
MA
Morocco
Prior art keywords
antibodies
antigen
lepr
binding fragments
bind
Prior art date
Application number
MA45801A
Other languages
English (en)
Other versions
MA45801B1 (fr
Inventor
Jesper Gromada
Panayiotis Stevis
Judith ALTAREJOS
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA45801A1 publication Critical patent/MA45801A1/fr
Publication of MA45801B1 publication Critical patent/MA45801B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des anticorps et des fragments de liaison à l'antigène d'anticorps qui se lient au récepteur de la leptine (lepr), et des procédés de leur utilisation. Selon certains modes de réalisation, l'invention concerne des anticorps et des fragments de liaison à l'antigène d'anticorps qui se lient au lepr et antagonisent la signalisation par lepr. Dans certains modes de réalisation, l'invention concerne des anticorps et des fragments de liaison à l'antigène d'anticorps qui se lient au lepr en présence ou en l'absence de leptine. Dans d'autres modes de réalisation, l'invention comprend des anticorps et des fragments de liaison à l'antigène d'anticorps qui présentent un agonisme partiel de la signalisation lepr. Les anticorps et les fragments de liaison à l'antigène de la présente invention sont utiles pour le traitement de divers états, comprenant, entre autres, la cachexie liée à l'insuffisance cardiaque congestive, la cachexie pulmonaire et la cachexie cancéreuse, les troubles auto-immuns tels que la maladie intestinale inflammatoire, le lupus érythémateux, la sclérose en plaques, le psoriasis, les maladies cardiovasculaires, l'hypertension artérielle, les troubles neurodégénératifs, la dépression, le cancer tel que le carcinome hépatocellulaire, le mélanome, le cancer du sein, et d'autres maladies et troubles associés à ou provoqués par une signalisation de leptine élevée.
MA45801A 2016-11-08 2017-11-08 Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptine MA45801B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662419062P 2016-11-08 2016-11-08
PCT/US2017/060690 WO2018089532A1 (fr) 2016-11-08 2017-11-08 Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptine

Publications (2)

Publication Number Publication Date
MA45801A1 true MA45801A1 (fr) 2020-07-29
MA45801B1 MA45801B1 (fr) 2021-11-30

Family

ID=60409473

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45801A MA45801B1 (fr) 2016-11-08 2017-11-08 Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptine

Country Status (29)

Country Link
US (3) US10550192B2 (fr)
EP (2) EP3538554B1 (fr)
JP (4) JP7042816B2 (fr)
KR (1) KR102563568B1 (fr)
CN (1) CN110167965A (fr)
AU (2) AU2017359439B2 (fr)
CA (1) CA3043365A1 (fr)
CL (3) CL2019001263A1 (fr)
CO (1) CO2019004672A2 (fr)
DK (1) DK3538554T3 (fr)
EA (1) EA201991075A1 (fr)
ES (1) ES3040144T3 (fr)
FI (1) FI3538554T3 (fr)
HR (1) HRP20251165T1 (fr)
HU (1) HUE073276T2 (fr)
IL (2) IL266426B (fr)
LT (1) LT3538554T (fr)
MA (1) MA45801B1 (fr)
MX (2) MX2019005397A (fr)
MY (2) MY203682A (fr)
PH (1) PH12019500988A1 (fr)
PL (1) PL3538554T3 (fr)
PT (1) PT3538554T (fr)
RS (1) RS67214B1 (fr)
SG (1) SG10201913470SA (fr)
SI (1) SI3538554T1 (fr)
SM (1) SMT202500327T1 (fr)
UA (1) UA127678C2 (fr)
WO (1) WO2018089532A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
EA201991075A1 (ru) 2016-11-08 2019-10-31 Антигенсвязывающие белки, которые проявляют антагонизм в отношении лептинового рецептора
KR20200100089A (ko) 2017-12-18 2020-08-25 리제너론 파마슈티칼스 인코포레이티드 렙틴 수용체 및/또는 gp130에 결합하는 이중 특이적 항원 결합 분자 및 이의 사용 방법
LT3773713T (lt) 2018-04-06 2025-08-25 Regeneron Pharmaceuticals, Inc. Leptino receptoriaus agonistinis antikūnas, skirtas kaulų masės didinimui subjektui, kuriam pasireiškia medžiagų apykaitos sutrikimas arba hipoleptinemija
WO2020016160A1 (fr) * 2018-07-16 2020-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthode de traitement de maladies neurologiques
MX2021007394A (es) 2018-12-18 2021-07-15 Regeneron Pharma Composiciones y metodos para aumentar el peso corporal y la masa muscular magra mediante el uso de antagonistas contra el receptor de leptina, gdf8 y activina a.
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US12616618B2 (en) * 2020-07-17 2026-05-05 Sumitomo Seika Chemicals Co., Ltd. Absorber with particles having water absorption and wettability properties
MX2023002995A (es) * 2020-09-15 2023-05-19 Regeneron Pharma Uso de agonistas de lepr para el dolor.
CN118436632B (zh) * 2024-07-05 2024-08-30 四川大学华西第二医院 Teriflunomide在制备预防和/或治疗原发性纤毛不动综合征的药物中的用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856098A (en) 1994-09-14 1999-01-05 Progenitor, Inc. Detection of a leptin receptor variant
US5912123A (en) 1994-09-14 1999-06-15 Progenitor, Inc. Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology
US5643748A (en) 1994-09-14 1997-07-01 Progenitor, Inc. HU-B1.219, a novel human hematopoietin receptor
US6451523B1 (en) 1994-09-14 2002-09-17 Interneuron Pharmaceuticals, Inc. Detection of a leptin receptor variant and methods for regulating obesity
US6977240B1 (en) 1995-11-27 2005-12-20 Millenium Pharmaceuticals, Inc. Methods of using the OB receptor antibodies to treat bodyweight disorders
US6482927B1 (en) 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
EP0885299B1 (fr) 1996-01-08 2005-10-26 Genentech, Inc. Recepteur et ligands ob
US7063958B1 (en) 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
AU2476301A (en) 1996-01-16 2001-05-24 Rockefeller University, The DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof
AU1833197A (en) 1996-01-18 1997-08-11 Progenitor, Inc. Detection of a leptin receptor variant and methods for regulating obesity
CA2244693A1 (fr) 1996-01-23 1997-07-31 Progenitor, Inc. Procedes d'utilisation du gene obese et de son produit genique afin de stimuler le developpement des cellules hematopoietiques
US7067472B1 (en) 1996-06-04 2006-06-27 The Scripps Research Institute Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies
US5965521A (en) 1997-02-25 1999-10-12 Eli Lilly Company Pulsatile delivery of leptin receptor ligands
IL120733A0 (en) 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
AU767068B2 (en) 1999-06-11 2003-10-30 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of leptin activity
US20040253242A1 (en) 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
FR2852397B1 (fr) 2003-03-10 2005-04-29 Utilisation des genes leprotl 1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal.
ES2289235T3 (es) * 2003-08-21 2008-02-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Nuevo antagonista de leptina.
DE10353593A1 (de) * 2003-11-17 2005-06-23 Klinikum der Universität München Großhadern-Innenstadt Leptinantagonist und Verfahren zur quantitativen Messung von Leptin
US7863240B2 (en) 2004-10-08 2011-01-04 Enzo Therapeutics, Inc. Methods and uses of leptin in hepatocellular carcinoma
US8969291B2 (en) 2004-10-08 2015-03-03 Enzo Therapeutics, Inc. Methods for decreasing leptin levels or activity for treating inflammation
EP1812038A1 (fr) 2004-11-18 2007-08-01 VIB vzw Domaine de fibronectine iii servant d'antagonistes de recepteurs de la leptine
US7307142B2 (en) * 2004-11-26 2007-12-11 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Leptin antagonists
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
WO2008140603A2 (fr) 2006-12-08 2008-11-20 Macrogenics, Inc. MÉTHODES POUR LE TRAITEMENT DE MALADIE AU MOYEN D'IMMUNOGLOBULINES COMPRENANT DES RÉGIONS FC QUI PRÉSENTENT DES AFFINITÉS ALTÉRÉES POUR FCγR D'ACTIVATION ET FCγR D'INHIBITION
GB0715216D0 (en) 2007-08-03 2007-09-12 Asterion Ltd Leptin
WO2010054007A1 (fr) 2008-11-07 2010-05-14 Fabrus Llc Bibliothèques combinatoires d'anticorps et leurs utilisations
KR101962483B1 (ko) 2010-11-17 2019-03-29 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
RU2013139267A (ru) 2011-02-10 2015-03-20 Рош Гликарт Аг Улучшенная иммунотерапия
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
EP2895513B1 (fr) 2012-09-12 2018-05-23 Genzyme Corporation Polypeptides comprenants le domaine fc ayant une glycosylation modifiee et une fonction effecteur reduite
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
MY185881A (en) * 2013-02-20 2021-06-14 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences
DK3108255T3 (da) 2014-02-18 2020-11-09 Inst Nat Sante Rech Med Fremgangsmåder og farmaceutiske sammensætninger til behandling af sygdomme medieret af nrp-1/obr-komplekssignalvejen
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
EA201991075A1 (ru) 2016-11-08 2019-10-31 Антигенсвязывающие белки, которые проявляют антагонизм в отношении лептинового рецептора

Also Published As

Publication number Publication date
FI3538554T3 (fi) 2025-09-24
MY191256A (en) 2022-06-10
SI3538554T1 (sl) 2025-10-30
HUE073276T2 (hu) 2026-01-28
ES3040144T3 (en) 2025-10-28
IL272358B (en) 2022-02-01
IL272358A (en) 2020-03-31
JP7042816B2 (ja) 2022-03-28
PL3538554T3 (pl) 2025-10-27
US11535675B2 (en) 2022-12-27
KR20190075133A (ko) 2019-06-28
HRP20251165T1 (hr) 2025-11-21
RS67214B1 (sr) 2025-10-31
MA45801B1 (fr) 2021-11-30
US20180127508A1 (en) 2018-05-10
JP2024109952A (ja) 2024-08-14
MX2019005397A (es) 2019-10-09
CA3043365A1 (fr) 2018-05-17
AU2025201454A1 (en) 2025-04-10
AU2017359439A1 (en) 2019-05-23
JP2020504078A (ja) 2020-02-06
JP2023093753A (ja) 2023-07-04
SMT202500327T1 (it) 2025-11-10
IL266426A (en) 2019-06-30
EA201991075A1 (ru) 2019-10-31
LT3538554T (lt) 2025-10-10
KR102563568B1 (ko) 2023-08-04
CL2020000549A1 (es) 2020-08-28
EP4613772A2 (fr) 2025-09-10
JP2022031969A (ja) 2022-02-22
DK3538554T3 (da) 2025-09-08
MY203682A (en) 2024-07-12
EP3538554B1 (fr) 2025-08-13
SG10201913470SA (en) 2020-03-30
JP7611292B2 (ja) 2025-01-09
IL266426B (en) 2020-11-30
EP3538554A1 (fr) 2019-09-18
CN110167965A (zh) 2019-08-23
PH12019500988A1 (en) 2019-08-19
US10550192B2 (en) 2020-02-04
CL2020001023A1 (es) 2020-10-09
CL2019001263A1 (es) 2019-09-27
MX2023011233A (es) 2023-10-03
EP4613772A3 (fr) 2025-12-24
US20200123264A1 (en) 2020-04-23
CO2019004672A2 (es) 2019-07-31
AU2017359439B2 (en) 2024-11-28
UA127678C2 (uk) 2023-11-29
PT3538554T (pt) 2025-09-01
WO2018089532A1 (fr) 2018-05-17
US20230235068A1 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
MA45801B1 (fr) Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptine
PH12022551750A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MA31135B1 (fr) Antagonistes de wnt et leur utilisation pour le diagnostic et le traitement de troubles a mediation wnt.
MX2022000397A (es) Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
WO2019014328A3 (fr) Anticorps agonistes qui lient cd137 humain et leurs utilisations
MA54538B1 (fr) Inhibiteurs d'apol1 et leurs procédés d'utilisation
MA31156B1 (fr) Modulateurs de partenaires de liaison de la sclerostine pour traiter des troubles lies aux os
MA40224B1 (fr) Anticorps se liant aux protofibrilles ass améliorés
TW200612908A (en) Antibodies against human interleukin-13 and uses therefor
DK1966244T3 (da) Anti-il-6-antistoffer der forebygger bindingen af il-6 sammensat af il-6ralfa til gp130
EA200870465A1 (ru) Антагонисты рецептора il-8
MA39313B1 (fr) Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers
MX2007008017A (es) Polipeptidos que se ligan a br3 y usos de los mismos.
FR3038517B1 (fr) Utilisation de fragments fc modifies en immunotherapie
MA37946B1 (fr) Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde
PL1631312T3 (pl) Kompozycje i sposoby terapii choroby zapalenia jelit
MXPA04001287A (es) Ensayo de receptor unido a proteina g.
MA33758B1 (fr) Polypeptides anti-tnfr1 stables, domaines variables de l'anticorps, et antagonistes
EA202092593A1 (ru) Белки, связывающие каннабиноидный рецептор 1-го типа (cb1), и их применение
MA52920B1 (fr) Compositions et procédés se rapportant à des agonistes de pyridinoylpipéridine 5-ht1f
EP4406592A3 (fr) Molécules de liaison thérapeutiques
DE602004031003D1 (de) Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden
WO2004008153A3 (fr) Diagnostique et therapie des maladies associees au recepteur presume de neurotransmetteurs chez l'humain (pnr)
ATE423100T1 (de) Neue chinolinverbindungen, die dazu in der lage sind, sich an den cb2-rezeptor zu binden
MA39555B1 (fr) Mutagenèse dirigée d'anticorps trem-1 pour réduire la viscosité